{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:36:32Z","timestamp":1791426992603,"version":"4.3.3"},"reference-count":63,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.vaccine.2017.07.051","type":"journal-article","created":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T17:17:04Z","timestamp":1501175824000},"page":"5402-5407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["MMR and MMRV vaccines"],"prefix":"10.1016","volume":"36","author":[{"given":"Frank","family":"Kowalzik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Knuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"44","key":"10.1016\/j.vaccine.2017.07.051_b0005","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.15585\/mmwr.mm6544a6","article-title":"Progress toward regional measles elimination \u2013 worldwide, 2000\u20132015","volume":"65","author":"Patel","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.07.051_b0010","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/bmj.295.6608.1264","article-title":"Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella","volume":"295","author":"B\u00f6ttiger","year":"1987","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.vaccine.2017.07.051_b0015","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1473-3099(08)70282-2","article-title":"Measles, mumps, and rubella in Finland: 25years of a nationwide elimination programme","volume":"8","author":"Peltola","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.051_b0020","doi-asserted-by":"crossref","first-page":"6918","DOI":"10.1016\/j.vaccine.2012.08.057","article-title":"Measles, mumps, and rubella virus vaccine (M-M-RII): a review of 32years of clinical and postmarketing experience","volume":"30","author":"Lievano","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.051_b0025","unstructured":"Centers for Disease Control and Prevention. Measles cases and outbreaks; June 2017. <https:\/\/www.cdc.gov\/measles\/cases-outbreaks.html>."},{"key":"10.1016\/j.vaccine.2017.07.051_b0035","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1016\/j.vaccine.2009.07.076","article-title":"A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile","volume":"27","author":"Czajka","year":"2009","journal-title":"Vaccine"},{"issue":"44","key":"10.1016\/j.vaccine.2017.07.051_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000001721","article-title":"Combination measles-mumps-rubella-varicella vaccine in healthy children","volume":"94","author":"Ma","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.vaccine.2017.07.051_b0045","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.vaccine.2013.12.011","article-title":"Risk of febrile convulsions after MMRV vaccination in comparison to MMR and MMR+V vaccination","volume":"32","author":"Shink","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.051_b0050","doi-asserted-by":"crossref","unstructured":"Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Cochrane Datab Syst Rev 2012(2).","DOI":"10.1002\/14651858.CD004407.pub3"},{"issue":"6","key":"10.1016\/j.vaccine.2017.07.051_b0055","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/jama.1973.03220330013003","article-title":"Immunologic properties of RA27-3 rubella virus vaccine. A comparison with strains presently licensed in the United States","volume":"225","author":"Plotkin","year":"1973","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.07.051_b0060","unstructured":"Information sheet. Observed rate of vaccine reactions. Varicella zoster virus vaccine. World Health Organization; 2012."},{"key":"10.1016\/j.vaccine.2017.07.051_b0065","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1358\/dot.2008.44.4.1210755","article-title":"A combination vaccine against measles, mumps, rubella and varicella","volume":"44","author":"Knuf","year":"2008","journal-title":"Drugs Today (Barcelona, Spain: 1998)"},{"key":"10.1016\/j.vaccine.2017.07.051_b0070","first-page":"1","article-title":"Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Marin","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2017.07.051_b0075","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1358\/dot.2006.42.5.973586","article-title":"A new combination vaccine for measles, mumps, rubella and varicella","volume":"42","author":"Zareba","year":"2006","journal-title":"Drugs Today (Barcelona, Spain: 1998)"},{"key":"10.1016\/j.vaccine.2017.07.051_b0080","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1097\/INF.0000000000001201","article-title":"Adverse events after MMR or MMRV vaccine in infants under nine months old","volume":"35","author":"Woo","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.07.051_b0085","unstructured":"Health NIo. ClinicalTrials.gov identifier: NCT00969436. Available at: <http:\/\/clinicaltrials.gov\/> [accessed May 12, 2014]."},{"key":"10.1016\/j.vaccine.2017.07.051_b0090","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s15010-007-6337-z","article-title":"Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9months of age","volume":"35","author":"Goh","year":"2007","journal-title":"Infection"},{"key":"10.1016\/j.vaccine.2017.07.051_b0095","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1542\/peds.2005-0092","article-title":"A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax","volume":"117","author":"Reisinger","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2017.07.051_b0100","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.vaccine.2008.10.064","article-title":"Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15months-2years or 2\u20136years primed with measles-mumps-rubella (MMR) vaccine","volume":"27","author":"Gillet","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.051_b0105","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.vaccine.2009.02.044","article-title":"Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age","volume":"27","author":"Halperin","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.051_b0110","unstructured":"GlaxoSmithKline. GlaxoSmithKline clinical trial register: 208136\/014 (MeMuRu-OKA-014). Available at: <http:\/\/www.gsk-clinicalstudyregister.com\/> [accessed May 16, 2014]."},{"key":"10.1016\/j.vaccine.2017.07.051_b0115","unstructured":"GlaxoSmithKline. GlaxoSmithKline clinical trial register: 208136\/016 (MeMuRu-OKA-016). Available at: <http:\/\/www.gsk-clinicalstudyregister.com\/> [accessed May 16, 2014]."},{"key":"10.1016\/j.vaccine.2017.07.051_b0120","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1097\/INF.0b013e318259fc8a","article-title":"Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis A and pneumococcal conjugate vaccines to children twelve to fourteen months of age","volume":"31","author":"Blatter","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2017.07.051_b0125","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1542\/peds.112.2.e98","article-title":"A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination","volume":"112","author":"Verstraeten","year":"2003","journal-title":"Pediatrics"},{"issue":"RR-04","key":"10.1016\/j.vaccine.2017.07.051_b0130","first-page":"1","article-title":"Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"McLean","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2017.07.051_b0135","unstructured":"Laura ER. Rubella in pregnancy. Uptodate; 2017. <https:\/\/www.uptodate.com\/contents\/rubella-in-pregnancy?source=related_link#H10>."},{"issue":"9","key":"10.1016\/j.vaccine.2017.07.051_b0140","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1097\/INF.0b013e318124a9f4","article-title":"Fetal risk associated with rubella vaccination during pregnancy","volume":"26","author":"Badilla","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"49","key":"10.1016\/j.vaccine.2017.07.051_b0145","first-page":"1117","article-title":"Revised ACIP recommendation for avoiding pregnancy after receiving a rubella-containing vaccine","volume":"50","author":"Centers for Disease Control and Prevention (CDC)","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.07.051_b0150","first-page":"1","article-title":"Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"47","author":"Watson","year":"1998","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2017.07.051_b0155","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/apa.13634","article-title":"Postexposure prophylaxis with intravenous immunoglobulin G prevents infants from getting measles","volume":"106","author":"Lejeune","year":"2017","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.vaccine.2017.07.051_b0160","unstructured":"Centers for Disease Control and Prevention. Rubella. In: Hamborsky J, Kroger A, Wolfe S, editors. Epidemiology and prevention of vaccine-preventable diseases. The pink book: course textbook, 13th ed. Washington, DC: Public Health Foundation; 2015. <http:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/index.html>."},{"key":"10.1016\/j.vaccine.2017.07.051_b0165","unstructured":"Mona M, Bialek SR. Infectious diseases related to travel: varicella (Chickenpox). Centre for Disease Control; 2016. p. 3. <https:\/\/wwwnc.cdc.gov\/travel\/yellowbook\/2016\/infectious-diseases-related-to-travel\/varicella-chickenpox>."},{"key":"10.1016\/j.vaccine.2017.07.051_b0170","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00006454-199601000-00020","article-title":"Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994)","volume":"15","author":"Beeler","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.07.051_b0175","doi-asserted-by":"crossref","first-page":"e687","DOI":"10.1542\/peds.2007-1578","article-title":"Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children","volume":"121","author":"France","year":"2008","journal-title":"Pediatrics"},{"issue":"RR-04","key":"10.1016\/j.vaccine.2017.07.051_b0180","first-page":"1","article-title":"Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"McLean","year":"2013","journal-title":"MMWR Recomm Rep"},{"issue":"9","key":"10.1016\/j.vaccine.2017.07.051_b0185","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/INF.0000000000001241","article-title":"Safety and immunogenicity of M-M-RII (combination measles-mumps-rubella vaccine) in clinical trials of healthy children conducted between 1988 and 2009","volume":"35","author":"Kuter","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"10.1016\/j.vaccine.2017.07.051_b0190","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00431-010-1142-6","article-title":"Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11\u201321months","volume":"169","author":"Knuf","year":"2010","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.vaccine.2017.07.051_b0195","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(86)91044-5","article-title":"Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins","volume":"1","author":"Peltola","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.07.051_b0200","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/jamapediatrics.2013.2745","article-title":"Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children","volume":"167","author":"Rowhani-Rahbar","year":"2013","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.vaccine.2017.07.051_b0205","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJMoa003077","article-title":"The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine","volume":"345","author":"Barlow","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.07.051_b0210","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.292.3.351","article-title":"MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis","volume":"292","author":"Vestergaard","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.07.051_b0215","doi-asserted-by":"crossref","unstructured":"Hambidge SJ, Newcomer SR, Narwaney KJ, Glanz JM, Daley MF, Xu S, et al. Timely versus delayed early childhood vaccination and seizures. Pediatrics 2014;133(6):e1492.","DOI":"10.1542\/peds.2013-3429"},{"issue":"31","key":"10.1016\/j.vaccine.2017.07.051_b0220","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1016\/j.vaccine.2015.06.009","article-title":"Risk of febrile seizure after measles-mumps-rubella-varicella vaccine: a systematic review and meta-analysis","volume":"33","author":"Ma","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.051_b0225","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.2010-0665","article-title":"Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures","volume":"126","author":"Klein","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2017.07.051_b0230","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1016\/j.vaccine.2009.05.056","article-title":"Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting","volume":"27","author":"Jacobsen","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.051_b0235","unstructured":"American Academy of Pediatrics. Measles. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, editors. Red book: 2015 report of the committee on infectious diseases, 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015. p. 535."},{"key":"10.1016\/j.vaccine.2017.07.051_b0240","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/oxfordjournals.aje.a113276","article-title":"A controlled comparison of joint reactions among women receiving one of two rubella vaccines","volume":"115","author":"Polk","year":"1982","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2017.07.051_b0245","first-page":"632","article-title":"Further studies with rubella vaccines in adults and children","volume":"207","author":"Marshall","year":"1971","journal-title":"Practitioner"},{"key":"10.1016\/j.vaccine.2017.07.051_b0250","first-page":"218","article-title":"Transient arthritis after rubella vaccination","volume":"118","author":"Cooper","year":"1969","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.vaccine.2017.07.051_b0255","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3181\/00379727-165-40979","article-title":"Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27\/3 rubella virus","volume":"165","author":"Weibel","year":"1980","journal-title":"Proc Soc Exp Biol Med"},{"issue":"19","key":"10.1016\/j.vaccine.2017.07.051_b0260","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1056\/NEJM199505113321904","article-title":"Safe administration of the measles vaccine to children allergic to eggs","volume":"332","author":"James","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.07.051_b0265","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0091-6749(95)70304-7","article-title":"IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines","volume":"96","author":"Sakaguchi","year":"1995","journal-title":"J AllergyClin Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.051_b0270","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jpeds.2009.10.015","article-title":"Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management","volume":"156","author":"Mantadakis","year":"2010","journal-title":"J Pediatr"},{"issue":"29","key":"10.1016\/j.vaccine.2017.07.051_b0275","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1016\/j.vaccine.2014.04.085","article-title":"Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies","volume":"32","author":"Taylor","year":"2014","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2017.07.051_b0280","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1001\/jama.2015.3077","article-title":"Autism occurrence by MMR vaccine status among US children with older siblings with and without autism","volume":"313","author":"Jain","year":"2015","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.vaccine.2017.07.051_b0285","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1464-5491.2011.03529.x","article-title":"Type 1 diabetes and measles, mumps and rubella childhood infections within the Italian Insulin-dependent Diabetes Registry","volume":"29","author":"Ramondetti","year":"2012","journal-title":"Diabet Med"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.051_b0290","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.vaccine.2011.10.087","article-title":"Vaccination and risk of type 1 diabetes mellitus in active component U.S. Military, 2002\u20132008","volume":"30","author":"Duderstadt","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2017.07.051_b0295","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00125-015-3800-8","article-title":"Vaccinations and childhood type 1 diabetes mellitus: a meta-analysis of observational studies","volume":"59","author":"Morgan","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.vaccine.2017.07.051_b0300","unstructured":"Centers for Disease Control and Prevention. Measles, mumps, and rubella (MMR) vaccination: what everyone should know; November 2016. <https:\/\/www.cdc.gov\/vaccines\/vpd\/mmr\/public\/index.html>."},{"key":"10.1016\/j.vaccine.2017.07.051_b0305","unstructured":"Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases varicella; November 2016. <https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/varicella.html#zostervirus>."},{"key":"10.1016\/j.vaccine.2017.07.051_b0310","unstructured":"Centers for Disease Control and Prevention. Reported cases and deaths from vaccine preventable diseases, United States, 1950\u20132013."},{"key":"10.1016\/j.vaccine.2017.07.051_b0315","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1080\/21645515.2016.1181243","article-title":"Issues in pediatric vaccine-preventable diseases in low- to middle-income countries","volume":"12","author":"Dbaibo","year":"2016","journal-title":"Hum Vaccine Immunother"},{"key":"10.1016\/j.vaccine.2017.07.051_b0320","first-page":"40","article-title":"A comparison of postelimination measles epidemiology in the United States, 2009\u20132014 versus 2001\u20132008","volume":"6","author":"Fiebelkorn","year":"2017","journal-title":"J Pediatric Infect Dis Soc"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17309593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17309593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T18:17:03Z","timestamp":1569953823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17309593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":63,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0264410X17309593"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.051","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MMR and MMRV vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}